This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Citrin, D. Articles by Camphausen, K. Search for Related Content PubMed PubMed Citation Articles by Citrin, D. Articles by Camphausen, K.

¹ Imaging and Molecular Therapeutics Section, Radiation Oncology Branch, ² Vascular Biology Faculty, and ³ Molecular Radiation Therapeutics Branch, National Cancer Institute, Bethesda, MD and ⁴ Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX

Requests for Reprints: Kevin Camphausen, Radiation Oncology Branch, National Cancer Institute, 10 Center Drive, Building 10, Room B3B69, Bethesda, MD 20892. Phone: (301) 496-5457; Fax: (301) 480-5439. E-mail: camphauk{at}mail.nih.gov

Endostatin is a potent inhibitor of angiogenesis currently in phase I clinical trials. Imaging technologies that use near-infrared fluorescent probes are well suited to the laboratory setting. The goal of this study was to determine whether endostatin labeled with a near-infrared probe (Cy5.5) could be detected in an animal and whether it would selectively localize to a tumor. Endostatin was conjugated to Cy5.5 monofunctional dye and injected into mice bearing Lewis lung carcinoma tumors (350 mm²). Mice were imaged at various time points while under sedation using a lightproof box affixed to a fluorescent microscope mounted with a filter in the near-infrared bandwidth consistent with Cy5.5 fluorescence. After i.p. injection, endostatin-Cy5.5 was absorbed producing a near-infrared fluorescent image within the tumors at 18 h reaching a maximum at 42 h after injection. No signal was emitted from mice injected with unlabeled endostatin or Cy5.5 dye alone or those that received no injection. Further results show that a dose response exists with injection of endostatin-Cy5.5. Mimicking the clinical route of administration, an i.v. injection had a peak signal emission at 3 h but also persisted to 72 h. Finally, to determine the intratumoral binding site for endostatin, we performed immunofluorescence on tumor specimens and demonstrated that endostatin binds to tumor vasculature and colocalizes with platelet/endothelial cell adhesion molecule 1 expression. This study demonstrates that endostatin covalently bound to Cy5.5 will migrate from a distant i.p. injection site to a tumor. These data indicate that endostatin-Cy5.5 is appropriate for selectively imaging tumors in uninjured experimental animals.

Received 11/ 3/03; revised 12/30/03; accepted 1/27/04.